Ionis Pharmaceuticals (NASDAQ:IONS) Shares Down 7.3% Following Analyst Downgrade

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) dropped 7.3% on Tuesday after Needham & Company LLC lowered their price target on the stock from $86.00 to $54.00. Needham & Company LLC currently has a buy rating on the stock. Ionis Pharmaceuticals traded as low as $29.21 and last traded at $28.7480. 978,814 shares were traded during trading, a decline of 64% from the average session volume of 2,736,926 shares. The stock had previously closed at $31.00.

Other research analysts also recently issued research reports about the company. Barclays cut their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. UBS Group began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. They set a “buy” rating and a $88.00 price objective for the company. JPMorgan Chase & Co. lowered their price target on shares of Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, September 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 8th. Nineteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $84.62.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. The trade was a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.81% of the company’s stock.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose about 55% year over year to $242.7 million, above estimates, and the quarterly loss was narrower than analysts expected. DAWNZERA sales also increased 40% to $37 million. Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue, Cuts TRYNGOLZA Sales Guidance
• Positive Sentiment: HC Wainwright and Needham retained “buy” ratings despite lowering their price targets to $70 and $54, respectively. Both targets remain above the cited current share price. Read More.; Read More.
• Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to about $50 million, down from its prior $100 million–$110 million forecast, citing slower uptake and competitive pressures. The disappointing launch outlook overshadowed the earnings beat and prompted a sharp selloff. Ionis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: The company’s 2026 revenue guidance of $875 million–$900 million is below the approximately $920.8 million analyst consensus, adding to concerns about the outlook. Ionis Q3 Revenue Rises; Lowers TRYNGOLZA Sales Outlook
• Neutral Sentiment: Law firms announced investigations following the forecast reduction. These notices are not findings of wrongdoing, but may add uncertainty for investors. Investigation Notice

Institutional Trading of Ionis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IONS. Alyeska Investment Group L.P. increased its holdings in Ionis Pharmaceuticals by 199.7% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock valued at $112,427,000 after buying an additional 944,766 shares during the period. Pictet Asset Management Holding SA lifted its position in Ionis Pharmaceuticals by 21.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,944,020 shares of the company’s stock valued at $87,249,000 after purchasing an additional 347,022 shares during the period. Bank of America Corp DE bought a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth $62,718,000. Groupama Asset Managment raised its holdings in Ionis Pharmaceuticals by 7.5% in the first quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock worth $61,915,000 after purchasing an additional 57,651 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $54,253,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. The stock has a market cap of $4.78 billion, a P/E ratio of -8.39 and a beta of 0.43. The stock has a fifty day simple moving average of $46.20 and a 200-day simple moving average of $65.63.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%. The business had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. During the same quarter in the prior year, the company posted ($0.80) earnings per share. Ionis Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. On average, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.